

A New Step Forward in Biologic Vision Enhancement - Transform™ now launched in Canada

Allotex receives Canadian clearance and launches Transform™, a human collagen-based implant enabling surgeons to offer natural vision correction.

CANADA, May 22, 2025 /EINPresswire.com/ -- Allotex, a global innovator in biologic vision

“

We're excited to introduce this innovative, biologic vision correction solution to our patients in Canada”

*Professor Guillermo Rocha,
MD*

technologies, announced today the launch of its [Transform™ implant](#) in Canada, marking a significant milestone in expanding access to natural, tissue-based solutions for vision enhancement. To support nationwide access and clinical implementation, Allotex has partnered with [Clarion Medical Technologies](#), one of Canada's leading ophthalmic technology distributors.

Transform is the first human collagen-based corneal

implant designed to be added to the eye, enabling surgeons to offer a tissue-based approach that complements the eye's natural structure. The quick outpatient procedure—typically completed in under 10 minutes—allows patients to enjoy everyday visual tasks without the constant hassle of reading glasses or contact lenses.

“At Allotex, we've developed a platform that combines biology with precision laser shaping,” said Michael Mrochen, PhD, CEO of Allotex. “It's designed to support surgeons in expanding what they can offer to patients who want a more natural solution.”

“We're excited to introduce this innovative, biologic solution to our patients in Canada,” said Professor Guillermo Rocha, MD, FRCSC, FACS, Chair of the Department of Ophthalmology & Visual Sciences at McGill University, and attending surgeon, Clinique Bellevue, Montreal. “This is a meaningful step forward for tissue addition technology in vision care—globally.”

Transform arrives at a time when more patients are actively seeking alternatives to external visual aids—looking to feel younger and be free from the daily hustle. Allotex's approach provides a biologic, reversible, and minimally invasive option, delivering new possibilities for surgeons and patients alike.

About Allotex

Allotex is a biotech-meets-ophthalmology company developing biologic vision correction technologies. Its human collagen-based corneal implants are designed to restore vision by adding tissue to the eye, not removing it—making the approach minimally invasive, reversible, and compatible with existing surgical infrastructure. With commercial activity in Europe, Canada, and other international regions, and regulatory momentum in the United States, Allotex is shaping the future of biologic refractive solutions.

About Clarion Medical Technologies

Clarion Medical Technologies is a leading provider in the Canadian eye care industry, dedicated to delivering innovative solutions that enhance ophthalmology and optometry practices. With over 30 years of experience, Clarion specializes in advanced technologies that optimize ophthalmic procedures and improve patient outcomes.

Michael Mrochen

Allotex

+1 617-640-2445

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/815035994>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.